After completing medical training at the University of Melbourne and Ph.D in Immunology at the Walter and Eliza Hall Institute in Australia, Andrew Cuthbertson spent five years doing molecular biology research as a staff member at the Howard Florey Institute in Melbourne and the National Institutes of Health in the United States. He then spent seven years at Genentech Inc. in San Francisco, working on anti–VEGF therapy for age-related macular degeneration.
Andrew was recruited to CSL Limited in 1997 and is the R&D Director and Chief Scientific Officer of CSL Limited.
In 2016, he was made an Enterprise Professor, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne and an Officer of the Order of Australia for his services to medical research.
Andrew has a keen interest in biopharmaceutical drug development. He currently manages an internal R&D budget of over US$600m, and a global R&D organisation of over 1,400 scientists. He is responsible for crafting the global R&D strategy for CSL.